Dopaminergic Modulation of Medial Prefrontal Cortex Deactivation in Parkinson Depression

Parkinson’s disease (PD) is associated with emotional abnormalities. Dopaminergic medications ameliorate Parkinsonian motor symptoms, but less is known regarding the impact of dopaminergic agents on affective processing, particularly in depressed PD (dPD) patients. The aim of this study was to exami...

Full description

Saved in:
Bibliographic Details
Main Authors: Anders H. Andersen, Charles D. Smith, John T. Slevin, Richard J. Kryscio, Catherine A. Martin, Frederick A. Schmitt, Lee X. Blonder
Format: Article
Language:English
Published: Wiley 2015-01-01
Series:Parkinson's Disease
Online Access:http://dx.doi.org/10.1155/2015/513452
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849685264289497088
author Anders H. Andersen
Charles D. Smith
John T. Slevin
Richard J. Kryscio
Catherine A. Martin
Frederick A. Schmitt
Lee X. Blonder
author_facet Anders H. Andersen
Charles D. Smith
John T. Slevin
Richard J. Kryscio
Catherine A. Martin
Frederick A. Schmitt
Lee X. Blonder
author_sort Anders H. Andersen
collection DOAJ
description Parkinson’s disease (PD) is associated with emotional abnormalities. Dopaminergic medications ameliorate Parkinsonian motor symptoms, but less is known regarding the impact of dopaminergic agents on affective processing, particularly in depressed PD (dPD) patients. The aim of this study was to examine the effects of dopaminergic pharmacotherapy on brain activation to emotional stimuli in depressed versus nondepressed Parkinson disease (ndPD) patients. Participants included 18 ndPD patients (11 men, 7 women) and 10 dPD patients (7 men, 3 women). Patients viewed photographs of emotional faces during functional MRI. Scans were performed while the patient was taking anti-Parkinson medication and the day after medication had been temporarily discontinued. Results indicate that dopaminergic medications have opposite effects in the prefrontal cortex depending upon depression status. DPD patients show greater deactivation in the ventromedial prefrontal cortex (VMPFC) on dopaminergic medications than off, while ndPD patients show greater deactivation in this region off drugs. The VMPFC is in the default-mode network (DMN). DMN activity is negatively correlated with activity in brain systems used for external visual attention. Thus dopaminergic medications may promote increased attention to external visual stimuli among dPD patients but impede normal suppression of DMN activity during external stimulation among ndPD patients.
format Article
id doaj-art-ba682ed17d5f4a41b9d6079d5a2c1e14
institution DOAJ
issn 2090-8083
2042-0080
language English
publishDate 2015-01-01
publisher Wiley
record_format Article
series Parkinson's Disease
spelling doaj-art-ba682ed17d5f4a41b9d6079d5a2c1e142025-08-20T03:23:12ZengWileyParkinson's Disease2090-80832042-00802015-01-01201510.1155/2015/513452513452Dopaminergic Modulation of Medial Prefrontal Cortex Deactivation in Parkinson DepressionAnders H. Andersen0Charles D. Smith1John T. Slevin2Richard J. Kryscio3Catherine A. Martin4Frederick A. Schmitt5Lee X. Blonder6Department of Anatomy and Neurobiology, University of Kentucky, Lexington, KY 40536, USAMagnetic Resonance Imaging and Spectroscopy Center, University of Kentucky, Lexington, KY 40536, USADepartment of Neurology, University of Kentucky, Lexington, KY 40536, USASanders-Brown Center on Aging, University of Kentucky, Lexington, KY 40536, USADepartment of Psychiatry, University of Kentucky, Lexington, KY 40536, USADepartment of Neurology, University of Kentucky, Lexington, KY 40536, USADepartment of Neurology, University of Kentucky, Lexington, KY 40536, USAParkinson’s disease (PD) is associated with emotional abnormalities. Dopaminergic medications ameliorate Parkinsonian motor symptoms, but less is known regarding the impact of dopaminergic agents on affective processing, particularly in depressed PD (dPD) patients. The aim of this study was to examine the effects of dopaminergic pharmacotherapy on brain activation to emotional stimuli in depressed versus nondepressed Parkinson disease (ndPD) patients. Participants included 18 ndPD patients (11 men, 7 women) and 10 dPD patients (7 men, 3 women). Patients viewed photographs of emotional faces during functional MRI. Scans were performed while the patient was taking anti-Parkinson medication and the day after medication had been temporarily discontinued. Results indicate that dopaminergic medications have opposite effects in the prefrontal cortex depending upon depression status. DPD patients show greater deactivation in the ventromedial prefrontal cortex (VMPFC) on dopaminergic medications than off, while ndPD patients show greater deactivation in this region off drugs. The VMPFC is in the default-mode network (DMN). DMN activity is negatively correlated with activity in brain systems used for external visual attention. Thus dopaminergic medications may promote increased attention to external visual stimuli among dPD patients but impede normal suppression of DMN activity during external stimulation among ndPD patients.http://dx.doi.org/10.1155/2015/513452
spellingShingle Anders H. Andersen
Charles D. Smith
John T. Slevin
Richard J. Kryscio
Catherine A. Martin
Frederick A. Schmitt
Lee X. Blonder
Dopaminergic Modulation of Medial Prefrontal Cortex Deactivation in Parkinson Depression
Parkinson's Disease
title Dopaminergic Modulation of Medial Prefrontal Cortex Deactivation in Parkinson Depression
title_full Dopaminergic Modulation of Medial Prefrontal Cortex Deactivation in Parkinson Depression
title_fullStr Dopaminergic Modulation of Medial Prefrontal Cortex Deactivation in Parkinson Depression
title_full_unstemmed Dopaminergic Modulation of Medial Prefrontal Cortex Deactivation in Parkinson Depression
title_short Dopaminergic Modulation of Medial Prefrontal Cortex Deactivation in Parkinson Depression
title_sort dopaminergic modulation of medial prefrontal cortex deactivation in parkinson depression
url http://dx.doi.org/10.1155/2015/513452
work_keys_str_mv AT andershandersen dopaminergicmodulationofmedialprefrontalcortexdeactivationinparkinsondepression
AT charlesdsmith dopaminergicmodulationofmedialprefrontalcortexdeactivationinparkinsondepression
AT johntslevin dopaminergicmodulationofmedialprefrontalcortexdeactivationinparkinsondepression
AT richardjkryscio dopaminergicmodulationofmedialprefrontalcortexdeactivationinparkinsondepression
AT catherineamartin dopaminergicmodulationofmedialprefrontalcortexdeactivationinparkinsondepression
AT frederickaschmitt dopaminergicmodulationofmedialprefrontalcortexdeactivationinparkinsondepression
AT leexblonder dopaminergicmodulationofmedialprefrontalcortexdeactivationinparkinsondepression